<DOC>
	<DOCNO>NCT02858024</DOCNO>
	<brief_summary>A Two-Cohort , Open-Label , Randomised , Three-Period Crossover Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine , Delivered By Dapivirine Vaginal Ring-004 , Containing 25 Mg Of Dapivirine</brief_summary>
	<brief_title>A Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine , Delivered By Dapivirine Vaginal Ring-004 , Containing 25 Mg Of Dapivirine</brief_title>
	<detailed_description />
	<criteria>Participants must meet follow criterion eligible enroll trial : 1 . Women 18 â‰¤ 40 year age give write informed consent ; 2 . Available visit consent follow procedure schedule trial ; 3 . Healthy , base medical history , vital sign , physical examination , urinalysis ( dipstick microscopy [ indicate ] ) , laboratory evaluation genital infection ( bacterial vaginosis , gonorrhoea , chlamydia , trichomonas ) , laboratory evaluation haematology biochemistry ; 4 . HIVnegative determine HIV test screening ; 5 . On stable oral contraceptive regimen least three month prior screen ; 6 . Upon pelvic examination time enrollment , cervix vagina appear normal determined Investigator/Physician ; 7 . Asymptomatic genital infection time enrollment ( woman diagnose treatable STI , either clinically laboratory test time screening , must complete treatment date enrollment ) ; 8 . Willing refrain use topical vaginal medication , vaginal product object , include female condom , cotton wool , rag , diaphragm , cervical cap ( vaginal barrier method ) , douche , lubricant , vibrators/dildos , dry agent seven day prior enrollment duration trial ; 9 . Willing refrain tampon use menses entire duration trial , assign Treatment B ( Cohort I ) ; 10 . Documentation abnormality cervical cytology , include grossly bloody smear , within 90 day prior screen ; 11 . Willing refrain participation research trial duration trial ; 12 . Willing provide adequate locator information trial retention purpose reachable per local standard procedure , e.g . home visit telephone , via family close neighbor contact ( confidentiality maintain ) ; 13 . Willing agree abstain follow total 2 day ( 48 hour ) prior trial visit ; Penilevaginal intercourse Oral contact genitalia 14 . Hepatitis B C negative time enrollment . Participants meet follow criterion NOT eligible enrol trial : 1 . Currently pregnant last pregnancy outcome within three month prior screen ; 2 . Currently breastfeed ; 3 . Currently within two month participation clinical research trial involve investigational market product prior screen ; 4 . Untreated symptomatic urogenital infection , e.g . urinary tract STIs , gynaecological condition vaginal itching , pain , discharge , within two week prior enrollment ; 5 . Have Grade 2 high pelvic examination finding , accord Division AIDS ( DAIDS ) Table Grading Severity Adult Pediatric Adverse Events ; Addendum 1 Female Genital Grading Table Use Microbicide Studies ; 6 . History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction , incontinence urge incontinence ; 7 . Current vulvar vaginal symptoms/abnormalities could influence trial result ; 8 . Cervical cytology screen require cryotherapy , biopsy , treatment ( infection ) , evaluation ; 9 . Symptomatic genital herpes simplex virus ( HSV ) infection history genital herpetic infection ; 10 . Any Grade 2 , 3 4 haematology , biochemistry urinalysis laboratory abnormality baseline ( screen ) accord DAIDS Table Grading Severity Adult Pediatric Adverse Events ; Addendum 1 Female Genital Grading Table Use Microbicide Studies ; 11 . Unexplained , abnormal bleed per vagina follow vaginal intercourse , gynaecologic surgery within 90 day prior enrollment ; 12 . Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone ; 13 . Any serious acute , chronic progressive disease ( e.g . know history neoplasm , cancer , diabetes , epilepsy , cardiac disease , autoimmune disease , HIV , AIDS , blood dyscrasia ) , sign cardiac disease , renal failure , severe malnutrition ; 14 . Have undergone hysterectomy and/or bilateral oophorectomy and/or present amenorrhea within 90 day prior enrollment ; 15 . Any condition ( ) , opinion Investigator , might interfere adherence trial requirement evaluation trial objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>